Niacin

Generic Name: Niacin

Brand Names: Advicor, Concept Ob, Irospan 24/6 Kit, Mvc-fluoride, Niacor, Niaspan, Niodan, Simcor, Vitafol-one

Drug Type: Small Molecule

Chemical Formula: C_₆H_₅NO_₂

CAS Number: 59-67-6

Unique Ingredient Identifier: 2679MF687A

Background: Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.

Indication: Niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections. Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia. It can also be used to reduce the risk of...

Associated Conditions: Atherosclerosis, High Cholesterol, High Triglyceride Level, Mixed Dyslipidemias, Nonfatal Myocardial Infarction, Pellagra, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Type II Hyperlipidaemia

Associated Therapies: Dietary supplementation

Clinical Trials

Short-term Effect of Extended-release Niacin on Endothelial Function.

Phase 4

Completed

Conditions: Hypoalphalipoproteinemia

Interventions: Drug: Niacin

First Posted Date: 2013-09-13

Last Posted Date: 2013-09-13

Lead Sponsor: University of Campinas, Brazil

Target Recruit Count: 18

Registration Number: NCT01942291

Locations: 🇧🇷
University of Campinas, Campinas, SP, Brazil

Benefit of Elevation of HDL-C in Women

Phase 4

Completed

Conditions: Cardiovascular Outcomes

Interventions: Drug: Placebo
Drug: Niaspan

First Posted Date: 2013-08-13

Last Posted Date: 2019-04-23

Lead Sponsor: Cedars-Sinai Medical Center

Target Recruit Count: 43

Registration Number: NCT01921010

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

Comparison of TRIA-662 500 mg and Niaspan 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: TRIA-662
Drug: Niaspan

First Posted Date: 2013-03-12

Last Posted Date: 2013-08-22

Lead Sponsor: Cortria Corporation

Target Recruit Count: 20

Registration Number: NCT01809301

Locations: 🇨🇦
Bio Pharma Services Inc. (BPSI), Toronto, Ontario, Canada

Niapsan as Add -on Therapy to Antipsychotic Treatment in First Episode Psychosis

Phase 3

Completed

Conditions: Psychosis

Interventions: Drug: Niaspan

First Posted Date: 2012-11-02

Last Posted Date: 2015-08-07

Lead Sponsor: Nova Scotia Health Authority

Target Recruit Count: 22

Registration Number: NCT01720095

Locations: 🇨🇦
NS Early Psychosis Program, Halifax, Nova Scotia, Canada

Nicotinic Acid Composition of HDL and Arterial Endothelium Function in Premature Coronary Heart Disease and High HDL

Phase 4

Terminated

Conditions: Dyslipidemias

Interventions: Drug: Placebo
Drug: Nicotinic acid

First Posted Date: 2011-10-12

Last Posted Date: 2013-01-29

Lead Sponsor: Xavier Pinto Sala

Target Recruit Count: 12

Registration Number: NCT01450410

Locations: 🇪🇸
Unitat Funcional de Risc Vascular. Servei Medicina Interna. Hospital Universitari de Bellvitge., L'Hospitalet de Llobregat, Barcelona, Spain

Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate

Phase 2

Completed

Conditions: HIV-1 Infection

Interventions: Drug: Fenofibrate
Drug: Niacin
Drug: Aspirin

First Posted Date: 2011-08-31

Last Posted Date: 2016-02-03

Lead Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Target Recruit Count: 99

Registration Number: NCT01426438

Locations: 🇺🇸
University of Colorado Hospital CRS (6101), Aurora, Colorado, United States
🇺🇸
NY Univ. HIV/AIDS CRS (401), New York, New York, United States
🇺🇸
University of Southern California (1201), Los Angeles, California, United States

and more 11 locations

Biosynthesis of PGD2 in Vivo

Not Applicable

Completed

Conditions: Hyperlipidemia

Interventions: Drug: Placebo
Drug: Aspirin
Drug: Niacin

First Posted Date: 2011-01-12

Last Posted Date: 2021-06-23

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 9

Registration Number: NCT01275300

Locations: 🇺🇸
University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States

Effect of Niacin on Transport of HDL and Relationship to Atherogenic Lipoproteins and Lipolysis

Not Applicable

Completed

Conditions: Dyslipidemias

Interventions: Other: Placebo
Drug: Niacin

First Posted Date: 2010-12-01

Last Posted Date: 2016-07-28

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 22

Registration Number: NCT01250990

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Study of the Effectiveness and Safety of Niaspan ® in the Treatment of Lipid Abnormalities in Latin America

Completed

Conditions: Cardiovascular Diseases

Interventions: Drug: Niacin

First Posted Date: 2010-09-13

Last Posted Date: 2014-06-06

Lead Sponsor: Abbott

Target Recruit Count: 128

Registration Number: NCT01200160

Locations: 🇲🇽
Site Reference ID/Investigator# 42110, Aguascalientes, Mexico
🇲🇽
Site Reference ID/Investigator# 42106, Mexico City DF, Mexico
🇲🇽
Site Reference ID/Investigator# 42104, Tijuana, Baja California Norte, Mexico

and more 19 locations

A Study of Niaspan on Endothelium-Dependent and Endothelium-Independent Vascular Reactivity (0000-093)

Phase 1

Completed

Conditions: Dyslipidemia

Interventions: Drug: Niaspan

First Posted Date: 2010-04-15

Last Posted Date: 2015-07-30

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 12

Registration Number: NCT01104519

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy